Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: Are all HMG-CoA reductase inhibitors alike?

Drugs and Aging

Volumn 25, Issue 8, 2008, Pages 649-664

  Maroo, Bijesh P ^a   Lavie, Carl J ^a,b,c   Milani, Richard V ^a  

^a JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c OCHSNER MEDICAL CENTER   (United States)

Author keywords

Atorvastatin, therapeutic use; Elderly; Fluvastatin, therapeutic use; HMG CoA reductase inhibitors, therapeutic use; Lovastatin, therapeutic use; Myocardial infarction, prevention; Pravastatin, therapeutic use; Rosuvastatin, therapeutic use

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN A; CYTOCHROME P450; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVINOLIN; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; STATIN; VERAPAMIL;

ACUTE HEART INFARCTION; AGED; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEATH; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FEMALE; GALLBLADDER DISEASE; HEART INFARCTION; HEPATOBILIARY DISEASE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; MALE; MYALGIA; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT;

AGE FACTORS; AGED; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MYOCARDIAL INFARCTION;

EID: 48249085778     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825080-00003     Document Type: Review

References (75)

1. Lavie CJ. Assessment and treatment of lipids in elderly persons. Am J Geriatr Cardiol 2004; 13 (3 Suppl. 1): 2-3
2. American Heart Association. Cardiovascular disease cost [online]. Available from URL: http://www.americanheart.org/presenter.jhtml?identifier=4475 [Accessed 2004 Mar 1]
3. 1988 monthly vital statistics report. Advanced data from vital and health statistics. Hyattsville (MD): National Center for Health Statistics, 1990
4. Lavie CJ, Milani R, Cassidy MM, et al. Benefits of cardiac rehabilitation and exercise training in older persons. Am J Geriatr Cardiol 1995; 4: 42-8
5. National hospital discharge survey. Washington, DC: US Dept of Health and Human Services, National Center for Health Statistics, 1987
6. Yusuf S. Furberg CD. Are we biased in our approach to treating elderly with heart disease? Am J Cardiol 1991; 68: 954-6
7. Montague TJ, Ikuta RM, Wong RY, et al. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two year period (1988-1989). Am J Cardiol 1991; 68: 843-7
8. Frye RL, Higgins MW, Beller GA, et al. Task force III: major demographic and epidemiology trends affecting adult cardiology. J Am Coll Cardiol 1988; 12: 840-6
9. Heiss G, Tamir I, Davis CE, et al. Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation 1980; 61: 302-15
10. Castelli WP, Wilson PW, Levy D, et al. Cardiovascular risk factors in the elderly. Am J Cardiol 1989; 63: 12-19H
11. Spencer G. Projections of populations of the United States by age, sex and race: 1988 to 2080. Washington, DC: US Bureau of the Census, 1999. Current population reports, series P-25, no. 1018
12. Black JS, Sefcik T, Kapoor W. Health promotion and disease prevention in the elderly: comparison of house staff and attending physician attitudes and practices. Arch Intern Med 1990; 150: 389-93
13. Aronow WS. Underutilization of lipid lowering drugs in older persons with prior myocardial infarction and serum low density lipoprotein cholesterol > 125mg/dl. Am J Cardiol 1998; 82: 668-9
14. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864-70
15. Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Am J Heart 2005; 149: 67-73
16. Alexander KP, Roe MT, Peterson ED, et al. Evolution in cardiovascular care for elderly patients with non-ST segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005; 46: 1479-87
17. Lewis SJ. Statin therapy in the elderly: observational and randomized controlled trials support event reduction. Am J Geriatr Cardiol 2004; 13 (3 Suppl. 1): 10-1
18. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-9
19. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211-8
20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9
21. Lewis SJ, Moye LA, Sacks FM, et al., for the CARE investigators. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med 1998; 129: 681-9
22. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Eng J Med 1998; 339: 1349-57
23. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001; 134 (10): 931-40
24. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7
25. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-900
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
27. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. PROSPER study group: PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002; 360: 1623-30
28. Shepherd J. A prospective study of pravastatin in the elderly at risk: new hope for older persons. Am J Geriatr Cardiol 2004; 13 (3 Suppl. 1): 17-24
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421
30. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published erratum appears in Circulation 2004 Aug 10; 110 (6): 763]. Circulation 2004; 110 (2): 227-39
31. Vaughan CJ, Gotto Jr AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35 (1): 1-10
32. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13
33. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. JAMA 2001; 285: 1711-8
34. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. MIRACL Study Investigators. Circulation 2002; 106: 1690-5
35. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators [published erratum appears in N Engl J Med 2006 Feb 16; 354 (7): 778]. N Engl J Med 2004; 350: 1495-504
36. Ray K, Bach R, Cannon CP, et al. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J 2006; 27: 2310-6
37. DeLemos JA, Blazing MA, Wiviott SD, et al. Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. A to Z Investigators. JAMA 2004; 292: 1307-16
38. Ridker PM, Cannon CP, Morrow D, et al. C reactive protein levels and outcomes after statin therapy: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22) Investigators. N Engl J Med 2005; 352: 20-8
39. Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs. event reduction and safety? Mayo Clin Proc 2007; 82 (5): 539-42
40. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007 Mar 13; 49: 1035-42
41. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004; 292 (11): 1365-7
42. Deedwania P, Stone PH, Bairery Merz CN, et al. Effects of intensive versus moderate lipid lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115: 700-7
43. Tobias DE, Pulliam CC. General and psychotherapeutic medication use in 878 nursing facilities: a 1997 National Survey. Consultant Pharmacist 1997; 18: 1401-8
44. Bottorff MB. Statin safety: what to know. Am J Geriatr Cardiol 2004; 13 (3 Suppl. 1): 34-8
45. Abernathy DR, Flockhart DA. Molecular basis of cardiolesterol vascular drug metabolism: implications for predicting clinically important drug interactions. Circulation 2000; 101: 1749-53
46. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med 2000; 160: 2273-80
47. Blum CB. Comparisons of properties of four inhibitors of 3-hydroxy-3 methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73: 3-11
48. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5
49. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042-51
50. Kinnman N, Hultcrantz R. Lipid lowering medication and hepatotoxicity. J Intern Med 2001; 250: 183-5
51. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22
52. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials. Circulation 2002; 105: 2341-6
53. US Food and Drug Administration, Center for Drug Evaluation and Research. Statins and hepatotoxicity [online]. Available from URL: http://www.fda.gov/ ohrms/dockets/ac/00/backgrd/3622b2b_safety_review.pdf [Accessed 2005 Aug 15]
54. Gotto Jr AM. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med 2003; 163:657-9
55. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-33
56. Phillips PS, Haas RH, Bannykh S, et al. Statin associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-5
57. Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165: 2671-6
58. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J
59. Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991; 91 (1B): 25S-30S
60. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085-92
61. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40
62. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid lowering drugs. JAMA 2004; 292: 2585-90
63. Alsheik-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111: 3051-7
64. Kasiske BL, Wanner C, O'Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006 Apr 17; 97 (8A): 82-85C
65. Athryos VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin fibrate combination in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80: 608-13
66. Keech A, Simes RJ, Barter P, et al. Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type II diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849-61
67. Courville KA, Lavie CJ, Milani RV. Lipid-lowering therapy for elderly patients at risk for coronary events and stroke. Am Heart Hosp J 2005; 3: 256-62
68. Menuet R, Lavie CJ, Milani RV. Importance and management of dyslipidemia in metabolic syndrome. Am J Med Sci 2005; 330: 295-302
69. Rosenson R. Lipid lowering with statins. In: Uptodate online version 15.3. Rose BD, editor. Waltham (MA): UpToDate, 2007 [online]. Available from URL: http://www.uptodate.com [Accessed 2007 Sep 20]
70. Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. Mayo Clin Proc 2005; 80 (9): 1163-8
71. Nissen SE, Tuzcu EM, Schoenhagen P, et al.; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291 (9): 1071-80
72. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81: 368-9
73. Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994; 74: 499-500
74. Grundy SM. The issue of statin safety: where do we stand? Circulation 2005; 111: 3016-9
75. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61